LiveLive
SPX7711.76000.4900%IXIC26402.42000.8500%FTSE10824.26000.0700%GOLD4456.40000.0000%SILVER66.50000.0000%PLATINUM1829.00000.0000%PALLADIUM1445.00000.0000%BRENT88.1000-0.5400%DJI53559.99000.5300%WTI83.40001.2600%NDX29433.43000.4300%NATGAS2.89004.2600%BTC78129.00000.5200%RUT2972.3700-1.5100%VIX14.4300-8.9600%ETH2457.72000.8200%DAX26569.99001.6600%BNB693.54000.6200%XRP1.39000.3600%CAC408401.1800-0.6100%NKY66405.56001.3400%DOGE0.09000.5900%HSI25584.7900-1.6300%ADA0.20000.6400%NIFTY24175.6500-0.1800%SOL105.12001.4600%AAPL319.70003.3500%SENSEX77264.5100-0.1400%MSFT513.53006.2700%TASI11158.8600-0.7000%IBOV175664.62002.7100%GOOGL346.59000.5100%TSLA348.7500-3.8900%MERVAL2979471.80002.2800%TSX36553.9200-0.1800%USD/PKR277.32000.3200%ASX2009092.30000.3700%EUR/PKR321.2300-0.5800%STI5699.93000.1900%GBP/PKR375.6700-0.6700%SAR/PKR73.84000.0000%FBMKLCI1725.8800-0.6000%AED/PKR75.48000.0000%SET1588.2200-0.7800%KOSPI6788.8800-1.7900%USD/EUR0.86000.8100%TWSE46331.45003.5100%GASOLINE3.0500-6.2300%HEATOIL4.25000.1200%COPPER6.6600-0.7500%WHEAT784.000014.3700%CORN536.50007.1900%SOYBEANS1288.00004.8900%COFFEE312.6000-15.8300%COCOA6636.000015.2300%SUGAR17.56001.6800%COTTON91.54005.1200%TRX0.34000.5700%AVAX7.32000.8700%LINK11.35000.2300%DOT0.84000.7200%LTC49.11000.3400%SHIB0.0000-0.1200%TON1.36000.3000%XLM0.18000.6100%HBAR0.07000.1400%SUI0.74000.0000%APT0.54000.6900%UNI4.810010.1000%PEPE0.00000.0900%NEAR1.87004.3800%ARB0.0900-0.9600%OP0.09000.6600%MATIC0.13000.0000%INJ5.19002.8800%FIL0.6800-0.5200%ICP2.4300-1.9300%STX0.00000.0000%ETC7.3800-1.2500%ALGO0.09000.9700%VET0.01004.7800%THETA0.1700-1.1100%FTM0.03000.0000%SAND0.0400-1.8300%MANA0.08002.3700%AXS0.90001.1100%GALA0.00001.8000%CRV0.3000-1.8200%MKR1600.87002.5300%AMZN266.43003.0200%NVDA217.55001.3200%META578.02005.1100%NFLX81.72002.6800%AMD465.5800-1.6200%AVGO368.79000.0900%JPM357.62001.7200%V381.60002.8500%MA595.30002.5300%XOM156.7100-5.0900%CVX201.8600-1.6600%KO89.6600-1.5800%PEP141.0700-1.6800%DIS108.10000.3000%BA209.8200-2.0400%BABA118.9000-0.3700%JD28.7400-2.1500%PDD85.6900-3.0400%NIO4.3700-5.6200%SPY769.35000.4700%QQQ716.43000.4200%DIA535.06000.5300%IWM295.7500-1.4000%GLD408.8900-3.4200%SLV60.0200-4.3000%TLT82.88001.0100%HYG79.74000.1600%LQD106.35000.4100%XLF58.10001.0800%XLK185.69001.3000%XLE62.6800-1.5100%XLV171.1600-1.9800%SMH553.1100-1.3000%ARKK84.5900-1.8800%EEM67.14000.0300%IBIT43.90000.5000%QAR/PKR76.15000.1200%INR/PKR2.91000.3000%JPY/PKR1.7300-0.7100%CAD/PKR199.4000-0.9300%AUD/PKR198.7600-0.0200%NZD/PKR164.0800-1.0400%MYR/PKR68.90000.3600%THB/PKR8.3600-1.4600%EUR/USD1.1600-0.8100%GBP/USD1.3500-0.8800%USD/JPY160.04000.7100%USD/CHF0.81001.0900%AUD/USD0.7200-0.1000%USD/CAD1.39000.7800%NZD/USD0.5900-1.0500%USD/INR95.3800-0.3300%USD/CNY6.7200-0.0100%USD/HKD7.84000.0000%USD/SGD1.27000.4200%USD/KRW1371.5000-0.9700%USD/TRY48.23000.3800%USD/ZAR16.18001.1300%USD/MXN17.03000.6700%USD/BRL5.21001.3300%USD/RUB85.78003.7000%USD/NGN1336.7000-0.8500%USD/EGP50.2000-1.3200%USD/KES129.36000.7300%USD/BDT123.19001.9700%USD/LKR327.80002.3700%USD/IDR17685.00000.1700%USD/THB33.13001.5300%USD/MYR4.0200-0.3600%USD/PHP62.25000.9600%USD/VND26070.0000-0.1500%USD/ILS3.00000.3700%USD/SAR3.75003.0200%USD/AED3.67000.0300%USD/QAR3.64003.6700%USD/KWD0.31000.1900%USD/BHD0.38002.8900%USD/OMR0.38000.4700%SPX7711.76000.4900%IXIC26402.42000.8500%FTSE10824.26000.0700%GOLD4456.40000.0000%SILVER66.50000.0000%PLATINUM1829.00000.0000%PALLADIUM1445.00000.0000%BRENT88.1000-0.5400%DJI53559.99000.5300%WTI83.40001.2600%NDX29433.43000.4300%NATGAS2.89004.2600%BTC78129.00000.5200%RUT2972.3700-1.5100%VIX14.4300-8.9600%ETH2457.72000.8200%DAX26569.99001.6600%BNB693.54000.6200%XRP1.39000.3600%CAC408401.1800-0.6100%NKY66405.56001.3400%DOGE0.09000.5900%HSI25584.7900-1.6300%ADA0.20000.6400%NIFTY24175.6500-0.1800%SOL105.12001.4600%AAPL319.70003.3500%SENSEX77264.5100-0.1400%MSFT513.53006.2700%TASI11158.8600-0.7000%IBOV175664.62002.7100%GOOGL346.59000.5100%TSLA348.7500-3.8900%MERVAL2979471.80002.2800%TSX36553.9200-0.1800%USD/PKR277.32000.3200%ASX2009092.30000.3700%EUR/PKR321.2300-0.5800%STI5699.93000.1900%GBP/PKR375.6700-0.6700%SAR/PKR73.84000.0000%FBMKLCI1725.8800-0.6000%AED/PKR75.48000.0000%SET1588.2200-0.7800%KOSPI6788.8800-1.7900%USD/EUR0.86000.8100%TWSE46331.45003.5100%GASOLINE3.0500-6.2300%HEATOIL4.25000.1200%COPPER6.6600-0.7500%WHEAT784.000014.3700%CORN536.50007.1900%SOYBEANS1288.00004.8900%COFFEE312.6000-15.8300%COCOA6636.000015.2300%SUGAR17.56001.6800%COTTON91.54005.1200%TRX0.34000.5700%AVAX7.32000.8700%LINK11.35000.2300%DOT0.84000.7200%LTC49.11000.3400%SHIB0.0000-0.1200%TON1.36000.3000%XLM0.18000.6100%HBAR0.07000.1400%SUI0.74000.0000%APT0.54000.6900%UNI4.810010.1000%PEPE0.00000.0900%NEAR1.87004.3800%ARB0.0900-0.9600%OP0.09000.6600%MATIC0.13000.0000%INJ5.19002.8800%FIL0.6800-0.5200%ICP2.4300-1.9300%STX0.00000.0000%ETC7.3800-1.2500%ALGO0.09000.9700%VET0.01004.7800%THETA0.1700-1.1100%FTM0.03000.0000%SAND0.0400-1.8300%MANA0.08002.3700%AXS0.90001.1100%GALA0.00001.8000%CRV0.3000-1.8200%MKR1600.87002.5300%AMZN266.43003.0200%NVDA217.55001.3200%META578.02005.1100%NFLX81.72002.6800%AMD465.5800-1.6200%AVGO368.79000.0900%JPM357.62001.7200%V381.60002.8500%MA595.30002.5300%XOM156.7100-5.0900%CVX201.8600-1.6600%KO89.6600-1.5800%PEP141.0700-1.6800%DIS108.10000.3000%BA209.8200-2.0400%BABA118.9000-0.3700%JD28.7400-2.1500%PDD85.6900-3.0400%NIO4.3700-5.6200%SPY769.35000.4700%QQQ716.43000.4200%DIA535.06000.5300%IWM295.7500-1.4000%GLD408.8900-3.4200%SLV60.0200-4.3000%TLT82.88001.0100%HYG79.74000.1600%LQD106.35000.4100%XLF58.10001.0800%XLK185.69001.3000%XLE62.6800-1.5100%XLV171.1600-1.9800%SMH553.1100-1.3000%ARKK84.5900-1.8800%EEM67.14000.0300%IBIT43.90000.5000%QAR/PKR76.15000.1200%INR/PKR2.91000.3000%JPY/PKR1.7300-0.7100%CAD/PKR199.4000-0.9300%AUD/PKR198.7600-0.0200%NZD/PKR164.0800-1.0400%MYR/PKR68.90000.3600%THB/PKR8.3600-1.4600%EUR/USD1.1600-0.8100%GBP/USD1.3500-0.8800%USD/JPY160.04000.7100%USD/CHF0.81001.0900%AUD/USD0.7200-0.1000%USD/CAD1.39000.7800%NZD/USD0.5900-1.0500%USD/INR95.3800-0.3300%USD/CNY6.7200-0.0100%USD/HKD7.84000.0000%USD/SGD1.27000.4200%USD/KRW1371.5000-0.9700%USD/TRY48.23000.3800%USD/ZAR16.18001.1300%USD/MXN17.03000.6700%USD/BRL5.21001.3300%USD/RUB85.78003.7000%USD/NGN1336.7000-0.8500%USD/EGP50.2000-1.3200%USD/KES129.36000.7300%USD/BDT123.19001.9700%USD/LKR327.80002.3700%USD/IDR17685.00000.1700%USD/THB33.13001.5300%USD/MYR4.0200-0.3600%USD/PHP62.25000.9600%USD/VND26070.0000-0.1500%USD/ILS3.00000.3700%USD/SAR3.75003.0200%USD/AED3.67000.0300%USD/QAR3.64003.6700%USD/KWD0.31000.1900%USD/BHD0.38002.8900%USD/OMR0.38000.4700%
Sunday, 30 August 2026
GuruAlpha
NICH Karachi Launches Specialized Pediatric Antiretroviral Therapy Center Under Dr. Wajid
World

NICH Karachi Launches Specialized Pediatric Antiretroviral Therapy Center Under Dr. Wajid

Karachi's National Institute of Child Health establishes Sindh's first dedicated pediatric ART center to tackle pediatric HIV with specialized dosing and clinical care.

GA

GuruAlpha News Desk

GuruAlpha News Desk

5 min read
ShareXFacebookWhatsApp

The National Institute of Child Health (NICH) in Karachi has launched a specialized Antiretroviral Therapy (ART) center dedicated to pediatric HIV care, operating under the supervision of Assistant Professor Dr. Wajid. This dedicated facility addresses a critical public health gap across Sindh by providing weight-adjusted antiretroviral regimens, specialized diagnostic monitoring, and clinical support tailored specifically to infants and young children living with HIV.

Dedicated Care for Pakistan's Youngest HIV Patients

For years, pediatric HIV patients in Sindh faced systemic barriers to receiving age-appropriate medical intervention. Most existing antiretroviral therapy centers in the province were designed primarily for adult populations, leaving children reliant on scaled-down adult tablets or fragmented medical advice. The opening of the specialized ART clinic at NICH fundamentally changes this dynamic by embedding HIV management directly within Pakistan's premier pediatric tertiary care hospital.

Under the leadership of Assistant Professor Dr. Wajid, the new center brings clinical oversight, viral load tracking, and continuous monitoring into a dedicated pediatric environment. The facility provides precise, weight-based liquid and dispersible pediatric ARV formulations, which are crucial for maintaining strict adherence and preventing drug resistance among infants and young children.

Children living with HIV require a medical architecture built specifically for their growing bodies and unique clinical needs. By centralizing pediatric HIV care within NICH, pediatricians can immediately address co-infections such as tuberculosis, severe acute malnutrition, and opportunistic bacterial illnesses that frequently endanger immunocompromised children.

The Legacy of Outbreaks and the Need for Specialized Infrastructure

The necessity for dedicated pediatric HIV infrastructure in Sindh became agonizingly clear following the 2019 Ratodero HIV outbreak in Larkana district, where hundreds of children tested positive for HIV due to unscreened blood transfusions, unsafe injection practices, and unlicensed medical providers. That crisis exposed how ill-equipped the health system was to handle pediatric HIV cases at scale, as primary care centers lacked basic pediatric formulations and trained medical staff.

In Pakistan, pediatric HIV cases stem from two major vectors: vertical transmission from mother to child during pregnancy or childbirth, and horizontal transmission caused by contaminated syringes, unsterilized medical instruments, and unsafe blood products. While maternal screening programs remain underdeveloped across rural districts, thousands of children contract the virus through systemic failures in infection control within private and informal health clinics.

Establishing an ART center at NICH directly targets these operational failures. As a tertiary referral hub, NICH receives pediatric patients from across Sindh and neighboring Balochistan. By offering free antiretroviral medication alongside comprehensive clinical evaluation, the new unit helps reverse the trend of high loss-to-follow-up rates that previously plagued pediatric HIV control efforts in southern Pakistan.

Clinical Complexities of Pediatric Antiretroviral Management

Treating HIV in children presents complex medical challenges that differentiate it sharply from adult therapy. Infants and young children experience rapid viral replication and accelerated disease progression if left untreated. Without immediate intervention, nearly half of HIV-positive infants die before their second birthday. However, when child-friendly antiretroviral regimens are initiated early, viral suppression rates match those of adult cohorts, allowing children to lead full, healthy lives.

The NICH ART center utilizes pediatric-friendly drug combinations, including fixed-dose combination dispersible tablets recommended by global health guidelines. These formulations eliminate the precise cutting or crushing of adult pills—a dangerous practice that previously led to toxic overdoses or therapeutic underdosing.

Beyond pharmacological management, the center provides crucial counseling services for parents and primary caregivers. Social stigma remains one of the largest obstacles to treatment adherence in Pakistan. Many families hide a child's HIV status due to fear of social ostracization, leading to missed clinic appointments and interrupted medication cycles. Dr. Wajid and the NICH clinical team have integrated confidential counseling rooms within the facility to educate families on treatment compliance, nutritional support, and long-term care management.

Overcoming Supply Chain Vulnerabilities and Operational Challenges

While the inauguration of the NICH ART center marks a vital step forward, maintaining its long-term success requires solving deep structural vulnerabilities. Pakistan's HIV response relies heavily on international funding mechanisms, particularly the Global Fund, to secure antiretroviral drugs. Fluctuations in international procurement, customs clearance delays, and supply chain disruptions have historically led to stock-outs of pediatric ARVs across provincial treatment centers.

To ensure continuous care, healthcare administrators must establish resilient local buffer stocks and streamline procurement logistics between the Sindh AIDS Control Program and central government agencies. Furthermore, training a broader workforce of pediatric nurses, clinical pharmacists, and social workers is essential to prevent medical burnout at NICH as patient volume increases.

The launch of this center sets a concrete precedent for pediatric healthcare in Pakistan. Expanding similar specialized units into regional medical centers in Sukkur, Larkana, and Hyderabad will be essential to ensure that every child affected by HIV across the province receives life-saving therapy near their home.

Frequently Asked Questions

What specific services does the newly established ART center at NICH Karachi provide?

The center provides specialized pediatric antiretroviral therapy, including age-appropriate liquid and dispersible drug formulations, viral load monitoring, and caregiver counseling. Operating under Assistant Professor Dr. Wajid, it offers full diagnostic and therapeutic management dedicated strictly to infants and children with HIV.

Why was a specialized pediatric ART center necessary at NICH rather than using adult facilities?

Children require weight-adjusted pediatric liquid or dispersible drug formulations rather than split adult pills, which risk dangerous overdoses or underdosing. The specialized center also manages pediatric-specific co-infections like tuberculosis and severe acute malnutrition while providing tailored psychological counseling for families.

What are the primary causes of pediatric HIV transmission in Sindh?

Pediatric HIV cases in Sindh primarily stem from vertical transmission from mother to child during pregnancy or delivery, as well as horizontal transmission caused by contaminated syringes, unsterilized medical instruments, and unsafe blood transfusions in informal healthcare settings.

Source:express.pk
Share this story
ShareXFacebookWhatsApp
Ad slot (in-content) — add ad unit ID in Admin → Settings
GA

GuruAlpha News Desk

The GuruAlpha News team delivers accurate, timely coverage of breaking news, markets, technology, and lifestyle — in English and Urdu.

NewsBreaking

Related Stories

All World

What is GuruAlpha?

GuruAlpha is a comprehensive digital platform offering live financial markets, free calculators, online tools, Islamic content, SIM packages, sports updates and celebrity profiles for Pakistan, Gulf countries and worldwide audiences.

Is GuruAlpha free to use?

Yes, GuruAlpha is completely free. All calculators, tools, market data, prayer times, Islamic resources and content are available without any subscription or sign-up.

Does GuruAlpha provide live market data?

Yes, GuruAlpha provides live market data including USD/PKR exchange rates, gold prices, cryptocurrency prices, stock market indices and commodity prices sourced from reliable financial data providers.

What calculators are available on GuruAlpha?

GuruAlpha offers over 1,200 calculators including Pakistan income tax, salary tax, PTA mobile tax, electricity bill, gold price, currency converter, Zakat calculator, property tax and many more.

Does GuruAlpha have Islamic prayer times?

Yes, GuruAlpha provides accurate prayer times for over 100 cities worldwide including Fajr, Dhuhr, Asr, Maghrib and Isha times. We also offer Qibla direction, Islamic calendar and Zakat calculator.